Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
Trial details
- Registry ID
- NCT07280299
- Drugs studied
- High Dose GT-02287, Low Dose GT-02287
TrialRedline tracks 1 clinical trial sponsored by Gain Therapeutics, Inc.: 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's DiseaseNCT07280299 | High Dose GT-02287, Low Dose GT-02287 | Not yet recruiting | 2028-06-30Estimated |
Names as written in the registry records.